Cottonoid Patties Shortage 2026: FDA Status and Steps

FDA listed neurosurgical patties, sponges, and strips under product code HBA as being in shortage on May 6, 2026, with the disruption estimated to continue through Q4 2026. The listing followed supplier issues and a manufacturing disruption that included Medline’s recall of every SKU in its branded neuro sponge category after higher-than-expected endotoxin findings.

That Q4 estimate was still present in the latest regulatory update reviewed here, dated June 16, 2026. It was a projection, not a guaranteed recovery date, and this is not a real-time inventory report. Check the live FDA Medical Device Shortages List, current recall instructions, and local supplier information before making purchasing or case-planning decisions.

Enter each required size or configuration, then test the FDA conservation steps against your facility’s own usage assumptions.

The FDA Shortage Covers the HBA Device Category

FDA’s formal category is “neurosurgical patties, sponges, and strips,” identified by product code HBA. The shortage-list reason was a shortage or discontinuance involving a device component, part, or accessory.

The national listing does not mean every brand, size, package configuration, distributor, or hospital has the same availability. A facility may have usable stock of one size while another is unavailable or on extended backorder. Inclusion on the list also does not, by itself, establish that patient care has been affected or quantify case delays, cancellations, injuries, fill rates, or local severity.

Three statuses therefore need separate records:

1. Regulatory shortage status: Whether HBA remains on FDA’s shortage list.
2. Recall status: Whether an exact manufacturer, catalog number, lot, or configuration is covered by current instructions.
3. Local availability: What unaffected inventory is usable, allocated, backordered, or confirmed for delivery.

A national shortage can remain in effect while a hospital has stock. A serious local backorder can also occur before or after a category appears on the national list.

Cottonoid Is Not a Universal Regulatory Synonym

FDA did not state that every product marketed as a cottonoid belongs to HBA. Cottonoid, cottonoid pattie, neuro pattie, surgical pattie, neuro sponge, and strip are related clinical or commercial terms, but they do not prove regulatory or clinical equivalence.

Term	Meaning In This Shortage
Cottonoid or cottonoid pattie	Common clinical or market wording, not a universal FDA synonym established by the available evidence
Neurosurgical pattie, sponge, or strip	FDA’s wording for the shortage category
HBA	Product code in the FDA shortage listing
Neuro or surgical pattie	Related wording that may describe products with different characteristics

Products carrying these names can differ in regulatory classification, intended use, material, dimensions, thickness, absorbency, linting, radiopaque-marker design, attached-string configuration, sterility, and package quantity. A shared function—absorbing fluid or protecting delicate tissue during neurosurgery and microsurgery—does not make two products interchangeable.

Do not use a preference-card description such as “small cottonoid” to reconcile a recall or approve a substitute. Connect the local name to the manufacturer, exact catalog number, dimensions, package presentation, intended use, and product code where available.

The Disruption Developed From March Through June

The available sources describe several stages rather than one universal shortage start date.

Date	Event	Operational Meaning
March 13	Medline customer communication	Higher-than-expected endotoxin levels reported for branded neurosurgical patties
April 8	Market tightening reported	Supplies of neuro sponges and strips were reportedly becoming constrained
May 6	FDA provider letter and listing	HBA category formally listed in shortage
June 16	Latest update reviewed here	Q4 2026 estimate remained on the shortage list

According to FDA’s letter to health care providers, Medline’s March 13 customer letter said higher-than-expected endotoxin levels had been identified on its branded neurosurgical pattie products. The finding suggested that out-of-specification endotoxin levels might be present in marketed products. It did not establish that every distributed unit was nonconforming.

FDA also reported that Medline’s product page said all SKUs in its branded neuro sponge category had been recalled and that there was no definite market re-entry date.

Sources used different March recall dates, including an early-March initiation, the March 13 customer notification, and a March 18 recall reference. Those dates may describe different administrative or communication steps. They should not be used to determine current scope or disposition requirements.

An April 8 market alert reported tightening supply and discussed allocations and whether suppliers were accepting new customers. Those statements help document conditions reported at the time, but they do not establish current inventory, production capacity, lead times, or customer eligibility.

FDA issued its provider communication and added HBA to the shortage list on May 6. The June 16 version of the list continued to estimate the shortage through Q4 2026.

The Medline Recall Is Not the Same as the National Shortage

The Medline recall applies to products covered by current recall documentation. The FDA shortage applies to the broader U.S. supply of neurosurgical patties, sponges, and strips under HBA.

That distinction has direct consequences:

• Scarcity does not make recalled inventory acceptable for use.
• Unaffected stock should not be removed solely because its device category is constrained.
• A Medline-branded item should not be presumed recalled or cleared from its general product name.
• Recall disposition and shortage conservation need separate owners and status fields.

Secondary reporting said Medline instructed customers to identify, quarantine, and destroy affected devices. Facilities must use current manufacturer and regulatory documentation—not copied product lists or historical reporting—to determine what action applies to an exact item.

A workable internal record separates products into those confirmed affected, confirmed unaffected, unresolved, and proposed substitutes awaiting review. “Unresolved” is not a disposition instruction. Those items should move through the facility’s authorized recall and risk-management process while staff obtain authoritative identification.

The Endotoxin Finding Created Four Reported Hazards

FDA identified four possible effects from affected products:

• Febrile response
• Local transient inflammation
• Hypotension
• Nausea

FDA stated that these effects may require medical or surgical intervention. This was a potential-hazard statement, not evidence that every product contained excessive endotoxin or that every exposure caused harm.

The evidence reviewed provides no percentage of nonconforming units, nationwide patient-harm estimate, national procedure-cancellation count, or national count of injuries or deaths attributable to the issue. Those figures were not supplied in the cited FDA materials.

OR and sterile-processing personnel should focus on exact product identification and the facility’s authorized recall process. Evaluation of possible patient exposure, symptoms, or treatment belongs with the responsible clinicians and institutional risk-management team.

FDA Prioritized Necessary Neural-Tissue Applications

FDA recommended limiting use to necessary cases and applying provider clinical judgment. It specifically identified these priority applications:

• Intracranial neurosurgery
• Protection of delicate neural tissue when alternatives are unsuitable
• Procedures requiring high absorbency with minimal linting

These are priority examples, not an exhaustive list of permitted uses. FDA did not state that every other application is inappropriate. Neuro patties, sponges, and strips may also be encountered in spine, shunt, ENT, and other microsurgical procedures, but presence on a preference card does not by itself establish priority.

A facility can distinguish between a case with no suitable reviewed alternative, a case in which an authorized alternative can perform the required function, and a case where several “just in case” packages are routinely opened but not used. Clinical governance and provider judgment should control that distinction rather than a procurement-only rule.

FDA’s Conservation Steps Target Opening, Allocation, and Visibility

FDA advised health care providers to open packages only as needed, centralize inventory management, avoid stockpiling, diversify supply sources where clinically appropriate, and consider FDA-authorized alternatives suitable for the application.

Open Only the Confirmed Configuration

Where workflow permits, staff can confirm the required size, shape, and configuration before opening a package onto the sterile field. Preference-card review can identify duplicate sizes and products routinely opened but not used.

Conservation cannot interfere with sterile technique, count procedures, emergency readiness, institutional policy, or clinician judgment. Its purpose is to prevent avoidable opening, not to improvise handling or delay care.

Centralize Usable and Kitted Inventory

Centralized management requires a dated count across the OR, sterile core, specialty carts, procedure areas, emergency reserves, approved off-site locations, and case kits. The record should distinguish usable stock from recalled, unresolved, committed, backordered, and confirmed inbound quantities.

At minimum, each line should identify the manufacturer, catalog number, local alias, dimensions, package presentation, recall status, usable quantity, scheduled commitments, recent consumption, and latest verification time. A combined total without configuration-level detail can overstate coverage when one essential size is the actual bottleneck.

Allocate by Clinical Requirement

A controlled-release pathway can record the planned procedure, required product characteristics, requested quantity, suitability of reviewed alternatives, and whether unused packages can remain unopened. This gives supply-chain staff the information needed to manage scarce stock without asking them to make clinical decisions.

FDA advised against stockpiling. A governed inventory target based on documented demand is different from uncontrolled accumulation driven by uncertainty. Central purchasing and visible allocation make that distinction auditable.

Diversify Through Reviewed Sources

Diversification does not mean purchasing any similarly named product from an available seller. Procurement should confirm the exact manufacturer, catalog number, regulatory status, intended use, sterility, package configuration, traceability, available quantity, allocation policy, lead time, and new-customer eligibility in dated written communication.

Supplier statements are time-sensitive. An April report that a manufacturer was under allocation or not accepting new customers does not establish the supplier’s later position.

Substitutes Require Application-Specific Review

FDA advised considering FDA-authorized alternatives appropriate to the specific application. Product names alone are not enough to approve a direct replacement.

Review Area	Required Comparison
Regulatory and clinical	Authorization or clearance, product code, intended use, manufacturer, and planned tissue interaction
Physical performance	Dimensions, thickness, shape, absorbency, and linting characteristics
Retained-item controls	Radiopaque marker, attached string, counting process, and documentation
Supply and workflow	Sterility, packaging, traceability, storage, availability, allocation, and education needs

A proposed alternative may change package-opening patterns, counts, case-cart assembly, storage, or retained-item documentation. Clinical, regulatory, value-analysis, procurement, OR, and sterile-processing reviewers should address those changes before broad adoption.

Commercial listings and market alerts can identify candidates, but they do not establish clinical equivalence or continuing supply. A controlled introduction may expose handling or workflow differences before the product is placed across multiple service lines.

Runway Depends on the First Required Size to Run Out

An aggregate count of all patties can conceal a critical shortage. If a procedure requires several configurations, the practical runway is generally limited by the required configuration with the fewest days of cover—not by the sum of unlike items.

The calculator above uses that bottleneck approach. For each entered configuration, weekly use equals weekly cases multiplied by units used per case. Days of cover equals usable units divided by weekly use, multiplied by seven. When conservation controls are selected, the calculation uses only the facility-entered estimate for unopened units avoided, priority case volume, or stock recovered through centralization.

FDA did not publish numerical percentages for how much those steps extend inventory. No universal reduction factor should be applied. The calculator therefore does not assume that opening only as needed saves a fixed percentage or that centralization automatically creates stock.

Runway remains conditional on case schedules, waste, emergency demand, substitute adoption, delayed deliveries, allocations, and recalled or unresolved inventory. Recalculate it when a count, schedule, delivery, or approved-use rule changes.

The Expected End Remained Q4 2026

The FDA information reviewed through June 16 estimated that the HBA shortage would continue through Q4 2026, also described as the end of 2026. It did not promise recovery on a particular date or simultaneous availability of every brand, size, and configuration.

Before relying on that estimate, verify whether FDA has revised the shortage entry, whether Medline has announced a documented market re-entry or changed recall instructions, and what approved suppliers can currently deliver to the facility. Neither “all cottonoids are unavailable” nor “the shortage is over” is reliable without product-specific and current documentation.